These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 30745819)

  • 21. A concise review of non-alcoholic fatty liver disease.
    Than NN; Newsome PN
    Atherosclerosis; 2015 Mar; 239(1):192-202. PubMed ID: 25617860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation.
    Farzanegi P; Dana A; Ebrahimpoor Z; Asadi M; Azarbayjani MA
    Eur J Sport Sci; 2019 Aug; 19(7):994-1003. PubMed ID: 30732555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease.
    Ore A; Akinloye OA
    Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30682878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
    Schuppan D; Schattenberg JM
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenylmethimazole abrogates diet-induced inflammation, glucose intolerance and NAFLD.
    Patton A; Church T; Wilson C; Thuma J; Goetz DJ; Berryman DE; List EO; Schwartz F; McCall KD
    J Endocrinol; 2018 Jun; 237(3):337-351. PubMed ID: 29666152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics.
    Portincasa P; Krawczyk M; Smyk W; Lammert F; Di Ciaula A
    Eur J Clin Invest; 2020 Oct; 50(10):e13338. PubMed ID: 32589264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular pathways of nonalcoholic fatty liver disease development and progression.
    Bessone F; Razori MV; Roma MG
    Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.
    Bibbò S; Ianiro G; Dore MP; Simonelli C; Newton EE; Cammarota G
    Mediators Inflamm; 2018; 2018():9321643. PubMed ID: 29563854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged PM2.5 exposure elevates risk of oxidative stress-driven nonalcoholic fatty liver disease by triggering increase of dyslipidemia.
    Xu MX; Ge CX; Qin YT; Gu TT; Lou DS; Li Q; Hu LF; Feng J; Huang P; Tan J
    Free Radic Biol Med; 2019 Jan; 130():542-556. PubMed ID: 30465824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis.
    Dornas W; Lagente V
    Pharmacol Res; 2019 Mar; 141():418-428. PubMed ID: 30658094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease.
    Wenfeng Z; Yakun W; Di M; Jianping G; Chuanxin W; Chun H
    Ann Hepatol; 2014; 13(5):489-95. PubMed ID: 25152980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
    Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
    J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppressing NLRP2 expression accelerates hepatic steatosis: A mechanism involving inflammation and oxidative stress.
    Li C; Liu Q; Xie L
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):22-29. PubMed ID: 30454891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review.
    Zaman CF; Sultana J; Dey P; Dutta J; Mustarin S; Tamanna N; Roy A; Bhowmick N; Khanam M; Sultana S; Chowdhury S; Khanam F; Sakibuzzaman M; Dutta P
    Cureus; 2022 Sep; 14(9):e29657. PubMed ID: 36320966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non‑alcoholic fatty liver disease mouse model.
    Lu Y; Lin Y; Huang X; Wu S; Wei J; Yang C
    Int J Mol Med; 2019 Jun; 43(6):2398-2408. PubMed ID: 30942432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How Inflammation Impinges on NAFLD: A Role for Kupffer Cells.
    Duarte N; Coelho IC; Patarrão RS; Almeida JI; Penha-Gonçalves C; Macedo MP
    Biomed Res Int; 2015; 2015():984578. PubMed ID: 26090470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease.
    Alberti G; Gana JC; Santos JL
    Nutrients; 2020 Nov; 12(11):. PubMed ID: 33212947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.